Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RGNX

Regenxbio Inc

Nov 10 • 04:00PM ET

11.02

-0.19 -1.69 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BMRN NTLA EDIT QURE SRPT ADVM BLUE VYGR CLLS

| Held by: VTI IWM XBI VXF IWN IBB SCHA FESM VTWO DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.49	Insider Own	8.59%	Shs Outstand	50.62M	Perf Week	-8.09%
Market Cap	557.86M	Forward P/E	-	EPS next Y	-1.72	Insider Trans	-1.29%	Shs Float	46.27M	Perf Month	0.92%
Enterprise Value	551.80M	PEG	-	EPS next Q	-0.74	Inst Own	83.27%	Short Float	10.55%	Perf Quarter	36.05%
Income	-177.91M	P/S	3.46	EPS this Y	32.56%	Inst Trans	-2.26%	Short Ratio	8.19	Perf Half Y	38.27%
Sales	161.32M	P/B	3.46	EPS next Y	44.46%	ROA	-34.07%	Short Interest	4.88M	Perf YTD	42.56%
Book/sh	3.19	P/C	2.03	EPS next 5Y	31.54%	ROE	-76.88%	52W High	13.93 -20.86%	Perf Year	16.86%
Cash/sh	5.42	P/FCF	-	EPS past 3/5Y	- -12.18%	ROIC	-46.97%	52W Low	5.03 118.87%	Perf 3Y	-47.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-43.84% 18.79%	Gross Margin	77.40%	Volatility	6.26% 6.16%	Perf 5Y	-61.59%
Dividend TTM	-	EV/Sales	3.42	EPS Y/Y TTM	30.69%	Oper. Margin	-96.04%	ATR (14)	0.75	Perf 10Y	-32.97%
Dividend Ex-Date	-	Quick Ratio	2.66	Sales Y/Y TTM	91.30%	Profit Margin	-110.29%	RSI (14)	43.57	Recom	1.42
Dividend Gr. 3/5Y	- -	Current Ratio	2.66	EPS Q/Q	-2.14%	SMA20	-10.01%	Beta	1.17	Target Price	31.25
Payout	-	Debt/Eq	1.66	Sales Q/Q	22.88%	SMA50	1.86%	Rel Volume	0.91	Prev Close	11.21
Employees	353	LT Debt/Eq	1.35	Earnings	Nov 06 BMO	SMA200	25.25%	Avg Volume	596.03K	Price	11.02
IPO	Sep 17, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.37% 19.78%	Trades		Volume	542,595	Change	-1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Downgrade	Goldman	Buy → Neutral	$38 → $14
Feb-07-25	Resumed	Raymond James	Outperform	$27
Nov-15-24	Resumed	Morgan Stanley	Overweight	$22
Oct-10-24	Resumed	Raymond James	Outperform	$18
Jun-07-24	Initiated	Goldman	Buy	$38
Mar-11-24	Initiated	H.C. Wainwright	Buy	$36
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$20 → $35
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$37
Feb-21-24	Resumed	Raymond James	Outperform	$45
Nov-01-23	Initiated	Stifel	Buy	$35
Jun-02-23	Initiated	Robert W. Baird	Outperform	$42
Jun-23-22	Initiated	Berenberg	Buy	$61
Dec-15-21	Initiated	Wedbush	Neutral	$29
Oct-19-21	Resumed	Morgan Stanley	Overweight	$62 → $50
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy	$60
Dec-16-20	Initiated	UBS	Buy	$57
Jun-25-20	Resumed	BofA/Merrill	Buy	$9
Jun-25-20	Resumed	BofA/Merrill	Buy	$60
May-13-20	Initiated	RBC Capital Mkts	Sector Perform	$42
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform	$38 → $37

Show Previous Ratings

Nov-06-25 02:08PM	Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:25AM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-30-25 07:05AM	REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program (PR Newswire)
07:05AM	Loading…
Oct-29-25 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-15-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire) +9.33%
Oct-09-25 07:05AM	REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting (PR Newswire)
Oct-06-25 07:05AM	REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD (PR Newswire)
Sep-29-25 07:05AM	REGENXBIO Announces Presentation at the World Muscle Society (PR Newswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 01:51PM	Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date (Benzinga)
07:05AM	REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE Trial of RGX-121 for Treatment of MPS II (PR Newswire)
Aug-28-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive) -7.81%
05:00PM	Loading…
Aug-18-25 05:00PM	REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II (PR Newswire)
Aug-12-25 08:50AM	Are Options Traders Betting on a Big Move in Regenxbio Stock? (Zacks) +8.58%
Aug-07-25 08:20AM	Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:18AM	Regenxbio: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
07:00AM	REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy (PR Newswire)
Aug-06-25 06:00PM	Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-31-25 07:05AM	REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Jul-24-25 08:55AM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jul-10-25 11:54AM	REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy (PR Newswire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +14.95%
Jun-05-25 07:05AM	REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -17.06%
Jun-02-25 07:05AM	REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire) +16.95%
07:00AM	Loading…
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive)
May-19-25 04:05PM	REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million (PR Newswire) +10.12%
May-14-25 07:47AM	FDA to review Regenxbio's gene therapy BLA for Hunter syndrome (Pharmaceutical Business Review)
07:13AM	FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment (PR Newswire)
May-13-25 09:44AM	Q1 2025 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II (PR Newswire)
03:09AM	Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks) +5.98%
04:23PM	Regenxbio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights (PR Newswire)
May-09-25 09:38AM	What To Expect From Regenxbio Inc (RGNX) Q1 2025 Earnings (GuruFocus.com) +5.17%
May-08-25 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting (PR Newswire)
May-06-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire) -18.85%
May-05-25 10:00AM	Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -6.15%
May-04-25 08:00AM	Investing Groups Roundtable: Tariff Policy Impact - Part 3 (Seeking Alpha)
May-03-25 10:24PM	The 1-Minute Market Report May 4, 2025 (Seeking Alpha)
May-01-25 05:35PM	Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.80%
Apr-30-25 04:05PM	REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights (PR Newswire)
Apr-28-25 10:25AM	The 1-Minute Market Report April 27, 2025 (Seeking Alpha)
Apr-22-25 05:30AM	Trumps FDA Sends a Bullish Signal to Biotech (The Wall Street Journal) +17.24%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -5.45%
Mar-29-25 08:30AM	Undercovered Dozen: Delek Logistics, Perma-Fix, Consolidated Water, Rockwell Automation + (Seeking Alpha)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-20-25 07:53AM	Regenxbios DMD gene therapy drives 122.3% biomarker uptick in three-year-old (Clinical Trials Arena)
Mar-19-25 09:15AM	REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE TRIAL OF RGX-202 GENE THERAPY (PR Newswire) +8.97%
Mar-14-25 09:39AM	Q4 2024 Regenxbio Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
Mar-13-25 05:25PM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates (PR Newswire)
Mar-10-25 07:05AM	REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire) -5.21%
Mar-06-25 10:00AM	Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know (Zacks)
04:09AM	Jim Cramer on REGENXBIO Inc. (RGNX): This Thing Just Does Nothing But Go Down (Insider Monkey)
Mar-04-25 07:31AM	REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases (PR Newswire)
Feb-26-25 04:05PM	REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights (PR Newswire)
Feb-25-25 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-11-25 03:20PM	Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns (Benzinga) -7.10%
Feb-10-25 09:55AM	Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet (Zacks)
Jan-30-25 07:05AM	REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 (PR Newswire) +5.05%
Jan-24-25 09:55AM	Wall Street Analysts See a 357.36% Upside in Regenxbio (RGNX): Can the Stock Really Move This High? (Zacks)
03:00AM	Gene therapies have been uneven for DMD but these companies hope to turn the tide (Pharma Voice)
Jan-15-25 03:18PM	Regenxbio and Nippon Shinyaku forge $810m gene therapy deal (Pharmaceutical Technology) +5.53%
Jan-14-25 06:30AM	Regenxbio licenses gene therapies to Japans Nippon Shinyaku (BioPharma Dive)
05:00AM	REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases (PR Newswire)
Jan-13-25 08:31AM	AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program (PR Newswire) -7.46%
Jan-08-25 07:26AM	Regenxbio price target lowered to $22 from $25 at BofA (TipRanks)
Dec-06-24 06:29PM	Apollo Global Management and Workday Set to Join SandP 500; Others to Join SandP MidCap 400 and SandP SmallCap 600 (PR Newswire) +9.61% +6.16%
06:29PM	Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-19-24 12:32PM	Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy (Pharmaceutical Technology) -5.81%
Nov-18-24 07:05AM	REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA (PR Newswire) +5.40%
05:23AM	FDA endorses speedy approval path for Regenxbio Duchenne gene therapy (BioPharma Dive)
Nov-14-24 07:05AM	REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE Trial of RGX-202 (PR Newswire)
Nov-07-24 02:22AM	Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... (GuruFocus.com) +18.66%
Nov-06-24 06:00PM	Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.72%
05:02PM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates (PR Newswire)
Nov-05-24 07:59AM	Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-30-24 07:05AM	REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights (PR Newswire)
Oct-21-24 07:05AM	REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 (PR Newswire) -6.58%
Oct-18-24 07:05AM	REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (PR Newswire)
Oct-17-24 03:04PM	JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc (GuruFocus.com)
Sep-23-24 04:05PM	REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference (PR Newswire)
Sep-17-24 07:05AM	REGENXBIO Appoints Mitchell Chan as Chief Financial Officer (PR Newswire)
Sep-04-24 09:15AM	New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth (GlobeNewswire)
Sep-03-24 01:33PM	RegenxBio touts positive data for rare disease drug RGX-121 (Pharmaceutical Technology) -7.20%
08:04AM	REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect (PR Newswire)
Aug-29-24 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-27-24 07:05AM	REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium (PR Newswire)

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simpson Curran	Chief Executive Officer	Oct 09 '25	Sale	12.62	20,811	262,635	216,162	Oct 10 06:38 PM
CURRAN M SIMPSON	Director	Oct 09 '25	Proposed Sale	12.22	20,811	254,310		Oct 09 04:19 PM
Simpson Curran	Chief Executive Officer	Sep 29 '25	Sale	10.03	7,624	76,469	236,973	Oct 01 05:02 PM
Simpson Curran	Chief Executive Officer	Sep 10 '25	Sale	10.02	7,734	77,495	244,597	Sep 12 04:30 PM
CURRAN M SIMPSON	Director	Sep 10 '25	Proposed Sale	9.89	15,358	151,891		Sep 10 04:38 PM
Mills Kenneth T.	Director	May 12 '25	Option Exercise	3.76	20,602	77,464	495,705	May 14 04:49 PM
Mills Kenneth T.	Director	May 12 '25	Sale	7.91	20,602	163,046	475,103	May 14 04:49 PM
KENNETH MILLS	Director	May 12 '25	Proposed Sale	7.52	20,602	154,927		May 12 04:29 PM
Mills Kenneth T.	Director	Mar 27 '25	Option Exercise	3.76	30,752	115,628	475,103	Mar 31 05:05 PM
VITTAL VASISTA	Officer	Dec 30 '24	Proposed Sale	7.41	20,041	148,504		Dec 30 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your FINVIZ experience